AMLX Amylyx Pharmaceuticals, Inc.
Price Chart
Executive Summary
Seven executives at Amylyx Pharmaceuticals, including both Co-CEOs, the CFO, CMO, and Chief Legal Officer, were awarded a total of approximately 1.8 million shares in a non-cash grant on March 5, 2026. These transactions are routine equity compensation awards and do not reflect open-market buying or selling activity.
Key Financial Metrics
Actionable Insight
Monitor upcoming 10-Q or proxy filing for details on the award terms (vesting, performance conditions). This cluster reflects routine compensation, not sentiment — no immediate trading signal.
Key Facts
- All 10 transactions were non-cash grants (Form 4 code 'A') of stock awards, totaling ~1.8 million shares.
- Executives involved include both Co-CEOs (Klee and Cohen), CFO (Frates), CMO (Bedrosian), and Chief Legal Officer (Mazzariello).
- No open-market purchases (P) or sales (S) were reported in the cluster.
- Total dollar value of transactions is $0 since no cash changed hands — these are standard equity compensation awards.
Financial Impact
$0 direct financial impact; ~1.8M shares granted, representing ~0.12% of market cap assuming $1.5B valuation and ~150M shares outstanding
Risk Factors
- Potential for modest future dilution as awarded shares vest.
- If awards are tied to aggressive performance targets, unmet goals could pressure management incentives.
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (10 trades, 7d window) | cluster-AMLX-1773086427668 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 23, 2026
6w ago
|
DEFA14A
| $17.32 $13.61 | ▼ −21.42% | ▼ −26.05% | $13.01 (−24.88%) |
|
Mar 2, 2026
14w ago
|
Insider Cluster
| $15.30 $12.76 | ▼ −16.60% | ▼ −8.66% | $13.01 (−14.97%) |
|
Feb 23, 2026
15w ago
|
Insider Cluster
| $13.90 $13.53 | ▲ +2.66% | ▼ −1.28% | $13.01 (+6.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access